Eli Lilly and Company has announced the appointment of Thomas J. Fuchs as its first Chief AI officer, effective October. 21, 2024. In this role, Fuchs will provide vision, strategic direction, and overall leadership of AI (artificial intelligence) initiatives across Lilly, including drug discovery, clinical trials, manufacturing, commercial activities and internal functions. He will also identify, build and manage AI and machine-learning solutions. 

Before joining Lilly, Fuchs was the Dean and inaugural Department Chair for AI and Human Health at Mount Sinai, Director of the Hasso Plattner Institute for Digital Health at Mount Sinai, and the Endowed Barbara T. Murphy Professor for AI and Computational Pathology at the Icahn School of Medicine at Mount Sinai. Prior to this, Fuchs held positions at Memorial Sloan Kettering Cancer Center, NASA’s Jet Propulsion Laboratory, and the California Institute of Technology, and founded three companies, including Paige AI. Fuchs holds a doctoral degree in machine learning from ETH Zurich, a research university in Zurich, Switzerland. and a master’s in technical mathematics from Graz Technical University in Austria. 

Source: Eli Lilly and Company